Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial

Blood (2022) 140 (Supplement 1): 1797–1799.

https://doi.org/10.1182/blood-2022-157255

Published: 2022

Journal Articles

Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2 V617F Variant Allele Frequency ≤1%

Giuseppe Gaetano Loscocco, Raffaella Santi, Carmela Mannarelli, Francesco Mannelli, Francesca Gesullo, Giacomo Coltro, Paola Guglielmelli, Umberto Gianelli, Alessandro M Vannucchi

Blood (2022) 140 (Supplement 1): 9714–9716.

https://doi.org/10.1182/blood-2022-167880

Published: 2022

Journal Articles

Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Chiara Paoli, Paola Guglielmelli, Francesco Mannelli, Miriam Borella, Vittorio Rosti, Elisa Rumi, Maria Chiara Finazzi, Oscar Borsani, Carmela Mannarelli, Maria Esposito, Mario Xhani, Lisa Pieri, Tiziano Barbui, Alessandro Rambaldi, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 6840–6841.

https://doi.org/10.1182/blood-2022-156566

Published: 2022

Journal Articles

Impact of Higher Calreticulin Gene Mutation Variant Allele Frequency in Patients with Myelofibrosis

Chiara Maccari, Benedetta Sordi, Paola Guglielmelli, Manjola Balliu, Alessandro Atanasio, Carmela Mannarelli, Giulio Capecchi, Ilaria Sestini, Giacomo Coltro, Giada Rotunno, Eva Angori, Filippo C. Borri, Natasha Szuber, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 3955–3956.

https://doi.org/10.1182/blood-2022-156773

Published: 2022

Journal Articles

Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience

Matteo Piccini, Sofia Pilerci, Barbara Scappini, Francesco Mannelli, Gaia Ciolli, Andrea Pasquini, Laura Fasano, Elisa Quinti, Paola Guglielmelli, Carmela Mannarelli, Fabiana Pancani, Michela Zizza, Leonardo Signori, Alessandro M. Vannucchi, Giacomo Gianfaldoni

Blood (2022) 140 (Supplement 1): 9008–9009.

https://doi.org/10.1182/blood-2022-163212

Published: 2022

Journal Articles

A Myelodepletive Phenotype Is Associated with Distinctive Molecular Features and Adverse Outcomes in Patients with Myelofibrosis

Giacomo Coltro, Francesco Mannelli, Giuseppe Gaetano Loscocco, Carmela Mannarelli, Giada Rotunno, Chiara Maccari, Fabiana Pancani, Alessandro Atanasio, Ayalew Tefferi, Alessandro Vannucchi, Paola Guglielmelli

Blood (2021) 138 (Supplement 1): 1498.

https://doi.org/10.1182/blood-2021-146600

Published: 2021

Journal Articles

Mutation Landscape and Prognostic Correlates of ASXL1 Variants in Primary and Secondary Myelofibrosis

Giacomo Coltro, Paola Guglielmelli, Giada Rotunno, Carmela Mannarelli, Chiara Maccari, Costanza Salvadori, Fiorenza Irushani Vanderwert, Francesco Mannelli, Cristina Salvati, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 2578.

https://doi.org/10.1182/blood-2021-148685

Published: 2021

Journal Articles

Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms

Fiorenza Irushani Vanderwert, Benedetta Sordi, Francesco Mannelli, Boaz Palterer, Francesca Gesullo, Valentina Mecheri, Raffaella Santi, Carmela Mannarelli, Francesca Crupi, Roberta Zanotti, Federica Irene Grifoni, Chiara Elena, Roberta Parente, Massimo Triggiani, Pieri Lisa, Fabio Almerigogna, Paola Guglielmelli, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 1500.

https://doi.org/10.1182/blood-2021-148154

Published: 2021

Journal Articles

A JAK2 V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis

Giuseppe Gaetano Loscocco, Paola Guglielmelli, Carmela Mannarelli, Elena Rossi, Francesco Mannelli, Francesco Ramundo, Giacomo Coltro, Silvia Betti, Chiara Maccari, Sara Ceglie, Chiara Paoli, Tiziano Barbui, Ayalew Tefferi, Valerio De Stefano, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 237.

https://doi.org/10.1182/blood-2021-147869

Published: 2021

Journal Articles

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Chiara Paoli, PhD, Paola Guglielmelli, MD PhD, Francesco Mannelli, MD, Lara Mannelli, MD, Vittorio Rosti, MD, Maria Chiara Finazzi, MD, Elisa Rumi, MD, Marco Ruggeri, Alessandro Pancrazzi, PhD, Carmela Mannarelli, PhD, Guido Finazzi, MD, Maria Luisa Ferrari, BSc, Laura Lissandrini, BSc, Duccio Fantoni, RN, Giovanni Barosi, Mario Cazzola, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 1662.

https://doi.org/10.1182/blood-2019-122837

Published: 2019

Journal Articles

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 2968.

https://doi.org/10.1182/blood-2019-129094

Published: 2019

Journal Articles

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation

Giada Rotunno, Carmela Mannarelli, Giada Brogi, Annalisa Pacilli, Francesca Gesullo, Francesco Mannelli, Sara Fiaccabrino, Benedetta Sordi, Chiara Paoli, Ilaria Marone, Elisa Rumi, Rossella Manfredini, Giovanni Barosi, Mario Cazzola, Alessandro M. Vannucchi, Paola Guglielmelli

Blood (2019) 133 (26): 2802–2808.

https://doi.org/10.1182/blood.2018879536

Published: 2019

Includes: Supplemental data

Journal Articles

Calreticulin Ins5 and Del52 Mutations Impair Unfolded Protein and Oxidative Stress Responses in Hematopoietic Cells

Simona Salati, PhD, Elena Genovese, BSc, Zelia Prudente, BSc, PhD, Chiara Carretta, Niccolò Bartalucci, PhD BSc, Valentina Pennucci, PhD, Samantha Ruberti, BSc, PhD, Chiara Rossi, PharmD, Sebastiano Rontauroli, BSc, Carmela Mannarelli, PhD, Roberta Zini, BSc, PhD, Elisa Bianchi, BSc, PhD, Paola Guglielmelli, MD PhD, Enrico Tagliafico, MDPhD, Alessandro M. Vannucchi, MD, Rossella Manfredini, PhD

Blood (2018) 132 (Supplement 1): 4332.

https://doi.org/10.1182/blood-2018-99-112550

Published: 2018

Journal Articles

JAK2 V617F Variant Allele Frequency Identifies Patients with Polycythemia Vera (PV) at High Risk for Venous Thrombosis

Paola Guglielmelli, MD PhD, Giacomo Coltro, MD, Giuseppe Gaetano Loscocco, MD, Benedetta Sordi, MD, Francesco Mannelli, MD, Chiara Paoli, PhD, Ilaria Marone, PhD, Alessandro Pancrazzi, PhD, Francesca Gesullo, BSci, Carmela Mannarelli, PhD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2018) 132 (Supplement 1): 1776.

https://doi.org/10.1182/blood-2018-99-112287

Published: 2018

Journal Articles

JAK2 Exon 12 Mutated Polycythemia Vera: The Mayo Clinic-University of Florence Experience with 33 Consecutive Cases and Comparison with JAK2 V617F Mutated Disease

Ayalew Tefferi, MD, Sravanthi Lavu, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Naseema Gangat, MBBS, Animesh Pardanani, MBBS, PhD, Curtis A. Hanson, MD, Carmela Mannarelli, MSc, PhD, Paola Guglielmelli, MD PhD, Alessandro M. Vannucchi

Blood (2017) 130 (Supplement 1): 4191.

https://doi.org/10.1182/blood.V130.Suppl_1.4191.4191

Published: 2017

Journal Articles

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

Alessandro M. Vannucchi, Annalisa Pacilli, PhD, Giada Rotunno, MSc, PhD, Francesco Mannelli, Chiara Paoli, BiSci, Carmela Mannarelli, MSc, PhD, Annalisa Franci, RN, Tiziana Fanelli, BiSc, Alessandro Pancrazzi, PhD, Francesca Gesullo, MSc, Giuditta Corbizi Fattori, BiSc, Alberto Bosi, MD, Paola Guglielmelli, MD PhD

Blood (2017) 130 (Supplement 1): 4195.

https://doi.org/10.1182/blood.V130.Suppl_1.4195.4195

Published: 2017

Journal Articles

MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis

Alessandro M. Vannucchi, Paola Guglielmelli, MD PhD, Terra L. Lasho, PhD, Giada Rotunno, MSc, PhD, Carmela Mannarelli, MSc, PhD, Annalisa Pacilli, PhD, Animesh Pardanani, MBBS PhD, Elisa Rumi, MD, Vittorio Rosti, MD, Curtis A. Hanson, MD, Francesco Mannelli, Rhett P. Ketterling, MD, Naseema Gangat, MBBS, Alessandro Rambaldi, MD Prof, Francesco Passamonti, MD, Giovanni Barosi, MD, Tiziano Barbui, MD, Ayalew Tefferi, MD

Blood (2017) 130 (Supplement 1): 200.

https://doi.org/10.1182/blood.V130.Suppl_1.200.200

Published: 2017

Journal Articles

The Role of the Axis TGF-β1/Mir-382-5p/SOD2 in the Induction of Oxidative Stress in CD34+ Hematopoietic Stem/Progenitor Cells from Primary Myelofibrosis

Chiara Rossi, PharmD, Roberta Zini, BSc, PhD, Samantha Ruberti, BSc, PhD, Sebastiano Rontauroli, BSc, Zelia Prudente, BSc, PhD, Greta Barbieri, BSc, Elisa Bianchi, BSc, PhD, Simona Salati, BSc, PhD, Elena Genovese, BSc, Carmela Mannarelli, MSc, PhD, Paola Guglielmelli, MD PhD, Enrico Tagliafico, MDPhD, Vittorio Rosti, MD, Giovanni Barosi, MD, Alessandro M. Vannucchi, Rossella Manfredini, BSc, PhD

Blood (2017) 130 (Supplement 1): 1655.

https://doi.org/10.1182/blood.V130.Suppl_1.1655.1655

Published: 2017

Journal Articles

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

Blood (2017) 130 (Supplement 1): 1657.

https://doi.org/10.1182/blood.V130.Suppl_1.1657.1657

Published: 2017

Journal Articles

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis

Blood (2017) 129 (24): 3227–3236.

https://doi.org/10.1182/blood-2017-01-761999

Published: 2017

Includes: Supplemental data

NARROW

Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial

Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2 V617F Variant Allele Frequency ≤1%

Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Impact of Higher Calreticulin Gene Mutation Variant Allele Frequency in Patients with Myelofibrosis

Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience

A Myelodepletive Phenotype Is Associated with Distinctive Molecular Features and Adverse Outcomes in Patients with Myelofibrosis

Mutation Landscape and Prognostic Correlates of ASXL1 Variants in Primary and Secondary Myelofibrosis

Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms

A JAK2 V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation

Calreticulin Ins5 and Del52 Mutations Impair Unfolded Protein and Oxidative Stress Responses in Hematopoietic Cells

JAK2 V617F Variant Allele Frequency Identifies Patients with Polycythemia Vera (PV) at High Risk for Venous Thrombosis

JAK2 Exon 12 Mutated Polycythemia Vera: The Mayo Clinic-University of Florence Experience with 33 Consecutive Cases and Comparison with JAK2 V617F Mutated Disease

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis

The Role of the Axis TGF-β1/Mir-382-5p/SOD2 in the Induction of Oxidative Stress in CD34+ Hematopoietic Stem/Progenitor Cells from Primary Myelofibrosis

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only